The Effectiveness of Traditional Chinese Medicine Jinlida Granules on Glycemic Variability in Newly Diagnosed Type 2 Diabetes: A Double-Blinded, Randomized Trial

Published on Oct 8, 2021in Experimental Diabetes Research
· DOI :10.1155/2021/6303063
Jiemin Pan10
Estimated H-index: 10
Yuejie Xu + 6 AuthorsWeiping Jia79
Estimated H-index: 79
This study aimed to evaluate the influence of Jinlida granules on glycemic variability with or without metformin treatment in patients with newly diagnosed type 2 diabetes. This study was a 16-week, double-blinded, randomized, controlled clinical trial. The enrolled patients with newly diagnosed type 2 diabetes were randomly divided into four groups: control, Jinlida, metformin, and combination treatment groups. A retrospective continuous glucose monitoring (CGM) system was used for subcutaneous interstitial glucose monitoring for 3 days consecutively. Hemoglobin A1c (HbA1c), traditional Chinese medicine symptom score, and CGM parameters, including glucose coefficient of variation, standard deviation of blood glucose values, and time in range of glucose 3.9–10.0 mmol/L, were assessed pre-test and post-test. A total of 138 participants completed the entire procedure. Compared with the pre-test, fasting plasma glucose, 2 hour postprandial plasma glucose, HbA1c, and traditional Chinese medicine symptom score all decreased in the four groups at the end of the test, and the combination treatment group showed the most significant decrease. In terms of CGM parameters, time in range of the Jinlida and metformin groups improved after intervention compared with the baseline (Jinlida group: 78.68 ± 26.15 versus 55.47 ± 33.29; metformin group: 87.29 ± 12.21 vs. 75.44 ± 25.42; P null ChiCTR-IOR-16009296 .
#1Jee Hee Yoo (Yonsei University)H-Index: 2
#2Min Sun Choi (SMC: Samsung Medical Center)H-Index: 3
Last. Jae Hyeon Kim (SMC: Samsung Medical Center)H-Index: 27
view all 9 authors...
BACKGROUND: As the use of continuous glucose monitoring (CGM) has increased, time in range (TIR) and other core CGM metrics are now emerging as the core metrics for clinical targets and assessing diabetic complications, beyond HbA1c. This study investigated the association between the CGM-derived TIR, hyperglycemia, hypoglycemia metrics, and albuminuria. METHODS: A total of 866 subjects with type 2 diabetes who underwent three or six days of CGM and had urinary albumin-to-creatinine ratio (ACR) ...
#1De Jin (Peking Union Medical College)H-Index: 7
#2Lili HouH-Index: 1
Last. Zhenhua JiaH-Index: 1
view all 13 authors...
Background: Metabolic syndrome (MS) is a powerful risk factor for cardiovascular and cerebrovascular diseases. Although lifestyle intervention reduces several of the symptoms of the syndrome and cardiovascular risks, the lifestyle intervention that yields the benefits is restrictive. Jinlida is a Chinese patent medicine that has shown activity in type 2 diabetes, which has been approved in China. Preclinical studies in Jinlida granules support an improved role of abnormal glucose and lipids meta...
#1Laura Mayeda (Virginia Mason Medical Center)H-Index: 1
#2Ronit Katz (UW: University of Washington)H-Index: 79
Last. Ian H. de Boer (UW: University of Washington)H-Index: 81
view all 10 authors...
​Objective Compared with hemoglobin A1c (HbA1c), continuous glucose monitoring (CGM) may better capture risk of diabetes complications in patients with chronic kidney disease (CKD), including diabetic peripheral neuropathy (DPN). We hypothesized that glucose time in range (TIR), measured by CGM, is associated with DPN symptoms among participants with type 2 diabetes mellitus (type 2 DM) and moderate-to-severe CKD. ​Research design and methods We enrolled 105 people with type 2 DM treated with in...
#1Weiping Jia (SJTU: Shanghai Jiao Tong University)H-Index: 79
#2Jianping Weng (USTC: University of Science and Technology of China)H-Index: 48
Last. Li Chen (SDU: Shandong University)H-Index: 118
view all 24 authors...
: The prevalence of diabetes in China has increased rapidly from 0.67% in 1980 to 10.4% in 2013, with the aging of the population and westernization of lifestyle. Since its foundation in 1991, the Chinese Diabetes Society (CDS) has been dedicated to improving academic exchange and the academic level of diabetes research in China. From 2003 to 2014, four versions of Chinese diabetes care guidelines have been published. The guidelines have played an important role in standardizing clinical practic...
#1Antonio CerielloH-Index: 109
#2Louis Monnier (University of Montpellier)H-Index: 34
Last. David R. Owens (Swansea University)H-Index: 69
view all 3 authors...
Summary Glycaemic variability is an integral component of glucose homoeostasis. Although it has not yet been definitively confirmed as an independent risk factor for diabetes complications, glycaemic variability can represent the presence of excess glycaemic excursions and, consequently, the risk of hyperglycaemia or hypoglycaemia. Glycaemic variability is currently defined by a large and increasing number of metrics, representing either short-term (within-day and between-day variability) or lon...
Abstract Background: There has been recent recognition of the limitations of hemoglobin A1C (HbA1C) in describing both short- and long-term glycemic control. Continuous glucose monitoring (CGM) pro...
#1Jingyi Lu (SJTU: Shanghai Jiao Tong University)H-Index: 14
#2Xiaojing Ma (SJTU: Shanghai Jiao Tong University)H-Index: 65
Last. Weiping Jia (SJTU: Shanghai Jiao Tong University)H-Index: 79
view all 11 authors...
OBJECTIVE Continuous glucose monitoring (CGM) has provided new measures of glycemic control that link to diabetes complications. This study investigated the association between the time in range (TIR) assessed by CGM and diabetic retinopathy (DR). RESEARCH DESIGN AND METHODS A total of 3,262 patients with type 2 diabetes were recruited. TIR was defined as the percentage of time spent within the glucose range of 3.9–10.0 mmol/L during a 24-h period. Measures of glycemic variability (GV) were asse...
#1Jiaxing Tian (Beijing University of Chinese Medicine)H-Index: 12
#2Fengmei LianH-Index: 14
Last. Xiaolin Tong (Peking Union Medical College)H-Index: 19
view all 4 authors...
Background Previous study found that the Chinese Herbal Medicine Jinlida could significantly enhance the hypoglycemic action of metformin compared to metformin alone. However, the advantage of Jinlida has not been clarified yet. We aimed to compare the efficacy of Jinlida in patients with T2DM based on stratification. Methods Data were analyzed from a 12-week, randomized, placebo-controlled, double-blind, multicenter study of Jinlida. The efficacy evaluation included HbA1c, FPG and 2hPG levels s...
Importance Previous studies have shown increasing prevalence of diabetes in China, which now has the world’s largest diabetes epidemic. Objectives To estimate the recent prevalence and to investigate the ethnic variation of diabetes and prediabetes in the Chinese adult population. Design, Setting, and Participants A nationally representative cross-sectional survey in 2013 in mainland China, which consisted of 170 287 participants. Exposures Fasting plasma glucose and hemoglobin A 1c levels were ...
#1Ya-Lin Shi (Ha Tai: Xiamen University)H-Index: 2
#2Wen-Juan Liu (FJUTCM: Fujian University of Traditional Chinese Medicine)H-Index: 1
Last. Shuyu Yang (Ha Tai: Xiamen University)H-Index: 21
view all 10 authors...
Background: Diabetes mellitus (DM) remains a major health problem worldwide. Several clinical trials have shown the superiority of the Traditional Chinese Medicine in delaying or reversing the development and progression of DM. This study aimed to evaluate the efficacy of Jinlida (JLD) granule, a Chinese herbal recipe, in the treatment of impaired glucose tolerance (IGT) and its effect on the prevention of DM. Methods: Sixty-five IGT patients were randomized to receive one bag of JLD granules th...
Cited By0
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.